-
Canan Schuman, PharmD/PhD
Posts
Here’s Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine
As of July 12, the number of new cases of COVID-19 in the U.S. has surpassed 60,000 for the fifth day in a row. Unfortunately,...
Brainstorm Cell Therapeutics : Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer’s Disease Program
NEW YORK, July 8, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key...
200 ALS Patients Finish Dosing in Phase 3 Trial of NurOwn Cell Therapy
Patient dosing has finished in the pivotal Phase 3 trial assessing the safety and efficacy of repeat administrations of NurOwn, a cell-based therapy for people with amyotrophic lateral sclerosis (ALS), BrainStorm...
BrainStorm to Showcase Alzheimer’s Disease Clinical Program in KOL Webinar
NEW YORK, July 1, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, will hold a Key...
Cannabis Companies Eyeing How Plant Could Help Autism Symptoms
After seeing some success around a treatment for epilepsy, the cannabis industry is increasingly eyeing for products for people with the autism spectrum disorder. Autism is a lifelong developmental...
BrainStorm to study stem cell treatment in Alzheimer’s patients
TEL AVIV (Reuters) – BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients...
BCLI: ALS ASSOCIATION AND I AM ALS AWARDS $500,000 GRANT; POTENTIAL INCLUSION IN RUSSELL 3000 INDEX…
$500,000 Grant from ALS Association and I AM ALS On June 9, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced a combined grant of $500,000 from the ALS...
AstraZeneca approaches Gilead about merging
NEW YORK — AstraZeneca PLC has made a preliminary approach to rival drug maker Gilead Sciences Inc. about a potential merger, according to people familiar...
FDA hits Novartis with unexpected 3-month delay on MS drug ofatumumab
Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed...